Thermo Fisher Scientific (NYSE:TMO – Get Free Report) is projected to post its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect the company to post earnings of $6.40 per share and revenue of $11.95 billion for the quarter. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 7:00 AM ET.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $4.28 EPS. On average, analysts expect Thermo Fisher Scientific to post $25.13 EPS for the current fiscal year and $27.53 EPS for the next fiscal year.
Thermo Fisher Scientific Trading Down 1.5%
Shares of NYSE TMO opened at $679.48 on Tuesday. The business has a 50 day simple moving average of $638.93 and a 200 day simple moving average of $549.90. Thermo Fisher Scientific has a 52 week low of $435.27 and a 52 week high of $704.00. The stock has a market cap of $251.24 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 2.89 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.
Analysts Set New Price Targets
A number of analysts have issued reports on the stock. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Guggenheim initiated coverage on shares of Thermo Fisher Scientific in a research report on Thursday. They set a “buy” rating on the stock. HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Finally, UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their target price for the company from $540.00 to $730.00 in a report on Tuesday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $654.05.
View Our Latest Analysis on Thermo Fisher Scientific
Insider Buying and Selling
In other Thermo Fisher Scientific news, CAO Joseph Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 73,768 shares of company stock worth $44,122,820 over the last ninety days. Company insiders own 0.33% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
